Report Detail

Pharma & Healthcare Global Tardive Dyskinesia (TD) Therapy Market Professional Survey Report 2019

  • RnM3811887
  • |
  • 11 October, 2019
  • |
  • Global
  • |
  • 101 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Table of Contents

    Executive Summary

      1 Industry Overview of Tardive Dyskinesia (TD) Therapy

      • 1.1 Definition of Tardive Dyskinesia (TD) Therapy
      • 1.2 Tardive Dyskinesia (TD) Therapy Segment by Type
        • 1.2.1 Global Tardive Dyskinesia (TD) Therapy Production Growth Rate Comparison by Types (2014-2025)
        • 1.2.2 Valbenazine
        • 1.2.3 Amantadine
        • 1.2.4 Tetrabenazine
        • 1.2.5 Clonazepam
        • 1.2.6 Others
      • 1.3 Tardive Dyskinesia (TD) Therapy Segment by Applications
        • 1.3.1 Global Tardive Dyskinesia (TD) Therapy Consumption Comparison by Applications (2014-2025)
        • 1.3.2 Hospitals
        • 1.3.3 Clinics
        • 1.3.4 Others
      • 1.4 Global Tardive Dyskinesia (TD) Therapy Overall Market
        • 1.4.1 Global Tardive Dyskinesia (TD) Therapy Revenue (2014-2025)
        • 1.4.2 Global Tardive Dyskinesia (TD) Therapy Production (2014-2025)
        • 1.4.3 North America Tardive Dyskinesia (TD) Therapy Status and Prospect (2014-2025)
        • 1.4.4 Europe Tardive Dyskinesia (TD) Therapy Status and Prospect (2014-2025)
        • 1.4.5 China Tardive Dyskinesia (TD) Therapy Status and Prospect (2014-2025)
        • 1.4.6 Japan Tardive Dyskinesia (TD) Therapy Status and Prospect (2014-2025)
        • 1.4.7 Southeast Asia Tardive Dyskinesia (TD) Therapy Status and Prospect (2014-2025)
        • 1.4.8 India Tardive Dyskinesia (TD) Therapy Status and Prospect (2014-2025)

      2 Manufacturing Cost Structure Analysis

      • 2.1 Raw Material and Suppliers
      • 2.2 Manufacturing Cost Structure Analysis of Tardive Dyskinesia (TD) Therapy
      • 2.3 Manufacturing Process Analysis of Tardive Dyskinesia (TD) Therapy
      • 2.4 Industry Chain Structure of Tardive Dyskinesia (TD) Therapy

      3 Development and Manufacturing Plants Analysis of Tardive Dyskinesia (TD) Therapy

      • 3.1 Capacity and Commercial Production Date
      • 3.2 Global Tardive Dyskinesia (TD) Therapy Manufacturing Plants Distribution
      • 3.3 Major Manufacturers Technology Source and Market Position of Tardive Dyskinesia (TD) Therapy
      • 3.4 Recent Development and Expansion Plans

      4 Key Figures of Major Manufacturers

      • 4.1 Tardive Dyskinesia (TD) Therapy Production and Capacity Analysis
      • 4.2 Tardive Dyskinesia (TD) Therapy Revenue Analysis
      • 4.3 Tardive Dyskinesia (TD) Therapy Price Analysis
      • 4.4 Market Concentration Degree

      5 Tardive Dyskinesia (TD) Therapy Regional Market Analysis

      • 5.1 Tardive Dyskinesia (TD) Therapy Production by Regions
        • 5.1.1 Global Tardive Dyskinesia (TD) Therapy Production by Regions
        • 5.1.2 Global Tardive Dyskinesia (TD) Therapy Revenue by Regions
      • 5.2 Tardive Dyskinesia (TD) Therapy Consumption by Regions
      • 5.3 North America Tardive Dyskinesia (TD) Therapy Market Analysis
        • 5.3.1 North America Tardive Dyskinesia (TD) Therapy Production
        • 5.3.2 North America Tardive Dyskinesia (TD) Therapy Revenue
        • 5.3.3 Key Manufacturers in North America
        • 5.3.4 North America Tardive Dyskinesia (TD) Therapy Import and Export
      • 5.4 Europe Tardive Dyskinesia (TD) Therapy Market Analysis
        • 5.4.1 Europe Tardive Dyskinesia (TD) Therapy Production
        • 5.4.2 Europe Tardive Dyskinesia (TD) Therapy Revenue
        • 5.4.3 Key Manufacturers in Europe
        • 5.4.4 Europe Tardive Dyskinesia (TD) Therapy Import and Export
      • 5.5 China Tardive Dyskinesia (TD) Therapy Market Analysis
        • 5.5.1 China Tardive Dyskinesia (TD) Therapy Production
        • 5.5.2 China Tardive Dyskinesia (TD) Therapy Revenue
        • 5.5.3 Key Manufacturers in China
        • 5.5.4 China Tardive Dyskinesia (TD) Therapy Import and Export
      • 5.6 Japan Tardive Dyskinesia (TD) Therapy Market Analysis
        • 5.6.1 Japan Tardive Dyskinesia (TD) Therapy Production
        • 5.6.2 Japan Tardive Dyskinesia (TD) Therapy Revenue
        • 5.6.3 Key Manufacturers in Japan
        • 5.6.4 Japan Tardive Dyskinesia (TD) Therapy Import and Export
      • 5.7 Southeast Asia Tardive Dyskinesia (TD) Therapy Market Analysis
        • 5.7.1 Southeast Asia Tardive Dyskinesia (TD) Therapy Production
        • 5.7.2 Southeast Asia Tardive Dyskinesia (TD) Therapy Revenue
        • 5.7.3 Key Manufacturers in Southeast Asia
        • 5.7.4 Southeast Asia Tardive Dyskinesia (TD) Therapy Import and Export
      • 5.8 India Tardive Dyskinesia (TD) Therapy Market Analysis
        • 5.8.1 India Tardive Dyskinesia (TD) Therapy Production
        • 5.8.2 India Tardive Dyskinesia (TD) Therapy Revenue
        • 5.8.3 Key Manufacturers in India
        • 5.8.4 India Tardive Dyskinesia (TD) Therapy Import and Export

      6 Tardive Dyskinesia (TD) Therapy Segment Market Analysis (by Type)

      • 6.1 Global Tardive Dyskinesia (TD) Therapy Production by Type
      • 6.2 Global Tardive Dyskinesia (TD) Therapy Revenue by Type
      • 6.3 Tardive Dyskinesia (TD) Therapy Price by Type

      7 Tardive Dyskinesia (TD) Therapy Segment Market Analysis (by Application)

      • 7.1 Global Tardive Dyskinesia (TD) Therapy Consumption by Application
      • 7.2 Global Tardive Dyskinesia (TD) Therapy Consumption Market Share by Application (2014-2019)

      8 Tardive Dyskinesia (TD) Therapy Major Manufacturers Analysis

      • 8.1 Teva Pharma
        • 8.1.1 Teva Pharma Tardive Dyskinesia (TD) Therapy Production Sites and Area Served
        • 8.1.2 Teva Pharma Product Introduction, Application and Specification
        • 8.1.3 Teva Pharma Tardive Dyskinesia (TD) Therapy Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.1.4 Main Business and Markets Served
      • 8.2 Biogen
        • 8.2.1 Biogen Tardive Dyskinesia (TD) Therapy Production Sites and Area Served
        • 8.2.2 Biogen Product Introduction, Application and Specification
        • 8.2.3 Biogen Tardive Dyskinesia (TD) Therapy Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.2.4 Main Business and Markets Served
      • 8.3 Johnson & Johnson
        • 8.3.1 Johnson & Johnson Tardive Dyskinesia (TD) Therapy Production Sites and Area Served
        • 8.3.2 Johnson & Johnson Product Introduction, Application and Specification
        • 8.3.3 Johnson & Johnson Tardive Dyskinesia (TD) Therapy Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.3.4 Main Business and Markets Served
      • 8.4 GlaxoSmithKline
        • 8.4.1 GlaxoSmithKline Tardive Dyskinesia (TD) Therapy Production Sites and Area Served
        • 8.4.2 GlaxoSmithKline Product Introduction, Application and Specification
        • 8.4.3 GlaxoSmithKline Tardive Dyskinesia (TD) Therapy Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.4.4 Main Business and Markets Served
      • 8.5 Neurocrine Biosciences
        • 8.5.1 Neurocrine Biosciences Tardive Dyskinesia (TD) Therapy Production Sites and Area Served
        • 8.5.2 Neurocrine Biosciences Product Introduction, Application and Specification
        • 8.5.3 Neurocrine Biosciences Tardive Dyskinesia (TD) Therapy Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.5.4 Main Business and Markets Served
      • 8.6 Pfizer
        • 8.6.1 Pfizer Tardive Dyskinesia (TD) Therapy Production Sites and Area Served
        • 8.6.2 Pfizer Product Introduction, Application and Specification
        • 8.6.3 Pfizer Tardive Dyskinesia (TD) Therapy Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.6.4 Main Business and Markets Served
      • 8.7 Novartis
        • 8.7.1 Novartis Tardive Dyskinesia (TD) Therapy Production Sites and Area Served
        • 8.7.2 Novartis Product Introduction, Application and Specification
        • 8.7.3 Novartis Tardive Dyskinesia (TD) Therapy Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.7.4 Main Business and Markets Served
      • 8.8 Sanofi
        • 8.8.1 Sanofi Tardive Dyskinesia (TD) Therapy Production Sites and Area Served
        • 8.8.2 Sanofi Product Introduction, Application and Specification
        • 8.8.3 Sanofi Tardive Dyskinesia (TD) Therapy Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.8.4 Main Business and Markets Served
      • 8.9 AstraZeneca
        • 8.9.1 AstraZeneca Tardive Dyskinesia (TD) Therapy Production Sites and Area Served
        • 8.9.2 AstraZeneca Product Introduction, Application and Specification
        • 8.9.3 AstraZeneca Tardive Dyskinesia (TD) Therapy Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.9.4 Main Business and Markets Served
      • 8.10 Bayer AG
        • 8.10.1 Bayer AG Tardive Dyskinesia (TD) Therapy Production Sites and Area Served
        • 8.10.2 Bayer AG Product Introduction, Application and Specification
        • 8.10.3 Bayer AG Tardive Dyskinesia (TD) Therapy Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.10.4 Main Business and Markets Served

      9 Development Trend of Analysis of Tardive Dyskinesia (TD) Therapy Market

      • 9.1 Global Tardive Dyskinesia (TD) Therapy Market Trend Analysis
        • 9.1.1 Global Tardive Dyskinesia (TD) Therapy Market Size (Volume and Value) Forecast 2019-2025
      • 9.2 Tardive Dyskinesia (TD) Therapy Regional Market Trend
        • 9.2.1 North America Tardive Dyskinesia (TD) Therapy Forecast 2019-2025
        • 9.2.2 Europe Tardive Dyskinesia (TD) Therapy Forecast 2019-2025
        • 9.2.3 China Tardive Dyskinesia (TD) Therapy Forecast 2019-2025
        • 9.2.4 Japan Tardive Dyskinesia (TD) Therapy Forecast 2019-2025
        • 9.2.5 Southeast Asia Tardive Dyskinesia (TD) Therapy Forecast 2019-2025
        • 9.2.6 India Tardive Dyskinesia (TD) Therapy Forecast 2019-2025
      • 9.3 Tardive Dyskinesia (TD) Therapy Market Trend (Product Type)
      • 9.4 Tardive Dyskinesia (TD) Therapy Market Trend (Application)
      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.3 Tardive Dyskinesia (TD) Therapy Customers

      11 Market Dynamics

      • 11.1 Market Trends
      • 11.2 Opportunities
      • 11.3 Market Drivers
      • 11.4 Challenges
      • 11.5 Influence Factors

      12 Conclusion

        13 Appendix

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        Tardive dyskinesia (TD) is a neurological disorder that has the involvement of the involuntary movements. The terms can be described as tardive which means delayed and dyskinesia which means abnormal movement. The symptoms of tardive dyskinesia include finger movement, facial grimacing, jaw swinging, repetitive chewing, continuous blinking of the eyes, tongue thrusting, and others. 

        The global Tardive Dyskinesia (TD) Therapy market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
        This report focuses on Tardive Dyskinesia (TD) Therapy volume and value at global level, regional level and company level. From a global perspective, this report represents overall Tardive Dyskinesia (TD) Therapy market size by analyzing historical data and future prospect.
        Regionally, this report categorizes the production, apparent consumption, export and import of Tardive Dyskinesia (TD) Therapy in North America, Europe, China, Japan, Southeast Asia and India.
        For each manufacturer covered, this report analyzes their Tardive Dyskinesia (TD) Therapy manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

        The following manufacturers are covered:
        Teva Pharma
        Biogen
        Johnson & Johnson
        GlaxoSmithKline
        Neurocrine Biosciences
        Pfizer
        Novartis
        Sanofi
        AstraZeneca
        Bayer AG

        Segment by Regions
        North America
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        Valbenazine
        Amantadine
        Tetrabenazine
        Clonazepam
        Others

        Segment by Application
        Hospitals
        Clinics
        Others


        Summary:
        Get latest Market Research Reports on Tardive Dyskinesia (TD) Therapy. Industry analysis & Market Report on Tardive Dyskinesia (TD) Therapy is a syndicated market report, published as Global Tardive Dyskinesia (TD) Therapy Market Professional Survey Report 2019. It is complete Research Study and Industry Analysis of Tardive Dyskinesia (TD) Therapy market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


        REPORT YOU MIGHT BE INTERESTED

        Purchase this Report

        $3,500.00
        $5,250.00
        $7,000.00
        2,739.75
        4,109.63
        5,479.50
        3,168.91
        4,753.37
        6,337.82
        380,660.00
        570,990.00
        761,320.00
        250,145.35
        375,218.03
        500,290.70
        Credit card Logo

        Related Reports


        Reason to Buy

        Request for Sample of this report